ScreenerHero
NEONeoGenomics, Inc.
NAS · US · Healthcare · Diagnostics & Research · neogenomics.com
16.24USD-2.49%Mkt Cap: 2.17B $P/E: —

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clin…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$226.85BUSDP/E 33.1
DAP
Danaher Corporation
$142.58BUSDP/E 38.5
DHR
Danaher Corporation
$151.78BUSDP/E 38.6
LONN
Lonza Group AG
$47.21BUSDP/E 38.3
NTRA
Natera, Inc.
$46.86BUSD
IDXX
IDEXX Laboratories, Inc.
$44.35BUSDP/E 39.5
A
Agilent Technologies, Inc.
$44.14BUSDP/E 31.4
IQV
IQVIA Holdings Inc
$41.03BUSDP/E 31.0
WAT
Waters Corporation
$40.83BUSDP/E 105.8
ILU
Illumina, Inc.
$30.40BUSDP/E 40.4
ILMN
Illumina, Inc.
$30.95BUSDP/E 38.2
MTD
Mettler-Toledo International, Inc.
$28.55BUSDP/E 32.1
LH
Labcorp Holdings Inc.
$26.80BUSDP/E 27.4
DGX
Quest Diagnostics Incorporated
$26.68BUSDP/E 25.6
GH
Guardant Health, Inc.
$21.92BUSD
MEDP
Medpace Holdings, Inc.
$16.98BUSDP/E 35.8
ERF
Eurofins Scientific SE
$13.65BUSDP/E 25.3
CRL
Charles River Laboratories International, Inc.
$13.84BUSD
RVTY
Revvity Inc. Common Stock
$13.33BUSDP/E 57.4
BIM
bioMérieux S.A.
$9.55BUSDP/E 19.1

Key Statistics

Company
Market Cap2.17B $
Enterprise Value2.43B $
Revenue (TTM)766.29M $
Gross Profit314.29M $
Net Income (TTM)-108.03M $
Revenue/Share5.942 USD
Last Price16.24 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.5K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)48.10
PEG2.09
EV/EBITDA99.75
EV/Revenue3.17
P/S2.77
P/B2.69
EPS (TTM)-0.39
EPS (Forward)0.34
52W Range
5.94094% of range16.92
52W High16.92 USD
52W Low5.940 USD
Profitability
Gross Margin43.21%
Oper. Margin-4.84%
EBITDA Margin3.17%
Profit Margin-14.85%
ROE-12.91%
ROA-7.94%
Growth
Revenue Growth11.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF5.23M $
CapEx (TTM)27.01M $
FCF Margin5.73%
FCF Yield2.02%
Net Debt302.83M $
Net Debt/EBITDA12.45
Balance Sheet
Debt/Equity0.49
Current Ratio3.60
Quick Ratio3.04
Book Value/Sh6.142 USD
Cash/Share1.133 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)19.72 USD
Upside (mean)+21.4%
Target Range16.00 USD – 35.00 USD
$16.00+21.4% to mean$35.00
# Analysts9
Ownership
Shares Out.130.21M
Float117.03M
Insiders2.07%
Institutions115.56%
Short Interest
Short Ratio4.9d
Short % Float14.16%
Short % Out.12.00%
Shares Short15.42M
Short (prev mo.)11.62M
Technical
SMA 5014.31 (+13.5%)
SMA 20011.27 (+44.1%)
Beta1.73
S&P 52W Chg18.16%
Avg Vol (30d)2.57M
Avg Vol (10d)1.63M
Technical Indicators
RSI (14)63.5
MACD0.7274
MACD Signal0.7606
MACD Hist.-0.0333
BB Upper17.76 USD
BB Middle15.49 USD
BB Lower13.22 USD
BB Width29.32%
ATR (14)0.6946 USD
Vol Ratio (20d)0.64x